Ultragenyx has announced that "the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for KRN23 for the treatment of X-linked hypophosphatemia (XLH). The MAA was filed and accepted in late 2016, and an opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in the second half of 2017."
You can read the full press release here: http://ir.ultragenyx.com/releasedetail.cfm?ReleaseID=1006547
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.